358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial by Peter Oppelt, Jingxia Liu, Douglas Adkins, Jessica Ley, Kevin Palka, Miriam Jacobs